??????????????????? ???????????????????????????????????Dr. Liao noted: "H002 has shown in preclinical experiments both equally potent and broad-spectrum things to do in opposition to a number of EGFR mutation mixtures, and significant selectivity and basic safety profile. The drug prospect has excellent opportunity to take care of prior EGFR-TKI re